Abstract
The objective of this study was to investigate the hypothesis that HPV vaccination administered in patients with low-grade (LG) cytology shortly after an initial colposcopic assessment could prospectively alter HPV-related biomarkers. This was a prospective pilot observational study involving women attending a colposcopy clinic for evaluation of abnormal LG cytology that were advised to undergo HPV vaccination and proceeded accordingly. These women were compared with a matched unvaccinated group. Women requiring cervical biopsies or CIN treatment were excluded. Intervention: A full three-dose HPV vaccination was undertaken with either the 2-valent or the 4-valent anti-HPV VLP vaccine. LBC samples were obtained prior and after the completion of the vaccination regimen and tested for HPV DNA genotyping (CLART-2 HPV test) and E6 and E7 mRNA (NASBA technique). Results: Alterations of HPV-related biomarkers at a colposcopy reassessment appointment 12 months later. Analysis: The p-values, relative risk (RR), absolute relative risk (ARR), number needed to treat (NNT) and 95% confidence intervals for each biomarker in each group were assessed. Results: A total of 309 women were included in the analysis. One hundred fifty-two women received the vaccine. HPV vaccination reduced in a statistically significant manner (p < 0.05) HPV DNA positivity rates for genotypes 16, 18, and 31, RR = 1.6 (95% CI: 1.1 to 2.3), RR = 1.7 (95% CI: 1.1 to 2.8), and RR = 1.8 (95% CI: 1.0 to 2.9), in women who only tested DNA-positive for HPV16, 18, and 31 genotypes, respectively, prior to vaccination. A less pronounced, statistically insignificant reduction was shown for women who tested positive for both HPV DNA and mRNA E6 and E7 expression for HPV16, 18, and 33 subtypes. Statistically significant reduction in HPV mRNA positivity was solely documented for genotype 31 (p = 0.0411). Conclusions: HPV vaccination appears to significantly affect the rates of HPV16, 18, and 31 DNA-positive infections in the population testing HPV DNA-positive for the aforementioned genotypes. The above findings deserve verification in larger cohorts.
Highlights
The consistent implementation of cervical cancer screening programs in the mid-1980s led to significant reductions in this neoplasm’s morbidity and mortality rates in several developed countries.More recently, the global launch of prophylactic HPV vaccination programs materialized primary cervical cancer prevention and empowered the aspiration of a possible disappearance of cervical cancer in the near future [1,2]
A total of 309 women were included to the final analysis of the study, subdivided in 20 separate subgroups in total based on the HPV subtype at the initial assessment (HPV DNA genotyping)
When the studied population was assessed as two groups, vaccinated vs. non-vaccinated women, irrelevant of the HPV mRNA status and the HPV subtype at the end of the study period, 85 individuals
Summary
The global launch of prophylactic HPV vaccination programs materialized primary cervical cancer prevention and empowered the aspiration of a possible disappearance of cervical cancer in the near future [1,2]. Cervical cancer screening and HPV vaccination programs are not being applied worldwide in a universal manner. Across Europe, large disparities are still observed between affluent and poorer countries in terms of primary and secondary cervical cancer prevention strategies and infrastructure. In Greece, despite several initiatives, no national cervical cancer screening program is currently in place, and most women are being opportunistically screened, predominantly by cytology and lately by HPV DNA and mRNA co-testing. Commencing in 2007, Greece was among the first countries to incorporate the anti-HPV vaccine (2-valent and 4-valent virus-like particle (VLP) vaccines) free of charge in the national immunization program. Throughout the study period, a vaccination strategy was ongoing with a primary cohort being adolescent girls from 12 to 15 years of age, while a catch-up cohort of older females up to the age of 26 was discontinued in December
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
